@inproceedings{44cdedcbf7a84ec0ae9010d2121476af,
title = "Quantitative assessment of proton beam dose and myocardial lesion formation detected by high-resolution, ex vivo delayed contrast-enhanced MRI for treatment of ventricular tachycardia",
abstract = "Proton beam therapy has the potential to non-invasively treat ventricular tachycardia (VT) by homogenizing infarct scar. It has been previously demonstrated that proton beam therapy can create lesions in healthy myocardial tissue, thereby suggesting a potential for treatment of VT. In prior work, we quantified the relationship between dose delivered to myocardial tissue with lesion formation identified with in vivo, delayed contrast-enhanced magnetic resonance imaging (DCE-MRI) scans. In the current work, we evaluate the relationship of delivered dose with lesions identified in high resolution, post-mortem DCE-MRI scans. Deformable registration is used to align the dose maps from the baseline planning CT scans to ex vivo scans following proton beam therapy in swine. The current study demonstrates that nearly 100% of tissue exposed to a dose of 30 Gy or higher developed into lesion and approximately 85% of the tissue in the 20-30 Gy interval developed into lesion. On the other hand, tissue exposed to doses of 10 Gy or less tended to remain healthy myocardium, with less than 10% of tissue in the 5-10 Gy range and almost no tissue in the 0-5 Gy range developing into lesion. ",
author = "Rettmann, {M. E.} and A. Suzuki and Deisher, {A. J.} and S. Hohmann and K. Imamura and J. Dickow and H. Konishi and S. Wang and Newman, {L. K.} and K. Parker and K. Monahan and Kruse, {J. J.} and K. Merrell and R. Foote and Herman, {M. G.} and Packer, {D. L.}",
note = "Funding Information: D.L. Packer receives research funding from the American Heart Association Foundation, Biosense Webster, Boston Scientific/EPT, CardioInsight, CardioFocus, Endosense, Hansen Medical, Medtronic CryoCth LP, NIH, St. Jude Medical, Siemens and Thermedical. Royalties from Wiley & Sons and St. Jude Medical. Dr. Packer and Mayo Clinic jointly have equity in a privately held company, External Beam Ablation Medical Devices. Mayo Clinic and D.L. Packer have a financial interest in mapping technology. In accordance with the Bayh-Dole Act, this technology has been licensed to St. Jude Medical, and Mayo Clinic and D.L. Packer have received annual royalties greater than $10,000, the federal threshold for significant financial interest. Funding Information: J.D. fellowship funding from the German Heart Foundation (S/06/19, Mit F{\"o}rdermitteln der Deutschen Herzs-tiftung e.V.). S.H. funding by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – project no. 380200397. Publisher Copyright: {\textcopyright} 2021 SPIE.; Medical Imaging 2021: Image-Guided Procedures, Robotic Interventions, and Modeling ; Conference date: 15-02-2021 Through 19-02-2021",
year = "2021",
doi = "10.1117/12.2582220",
language = "English (US)",
series = "Progress in Biomedical Optics and Imaging - Proceedings of SPIE",
publisher = "SPIE",
editor = "Linte, {Cristian A.} and Siewerdsen, {Jeffrey H.}",
booktitle = "Medical Imaging 2021",
}